
CBE ID

0559

Title

Combination chemotherapy or chemo-immunotherapy (if HER2 positive), is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0 or stage IB - III hormone receptor negative breast cancer

Project

Cancer

Endorsement Status

Endorsement Removed

Is Under Review

No

Previous Endorsement Cycle

Spring 2020

Removal Date

Mon, 11/09/2020 - 19:00

Initial Endorsement

Wed, 02/28/2007 - 19:00

Steward

American College of Surgeons

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

Percentage of female patients, age ≥ 18 and < 70 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), at AJCC stage T1cN0M0 or Stage IB - IIIC, whose primary tumor is of the breast, and progesterone and estrogen receptor negative is recommended or administered multi-agent chemotherapy within 4 months (120 days) of diagnosis

1.7 Measure Type

Process

1.8 Level of Analysis

Facility

1.9 Care Setting

Inpatient/Hospital

1.14 Numerator

Combination chemotherapy or chemo-immunotherapy (if HER2 positive), is recommended or administered within 4 months (120 days) of diagnosis

1.15 Denominator

Include if all of the following characteristics are identified: Women Age 18-69 at time of diagnosis Known or assumed first or only cancer diagnosis Epithelial malignancy only Primary tumors of the breast Invasive tumors Surgical procedure of primary site AJCC T1cN0M0, or AJCC Stage IB to IIIC Primary tumor is estrogen receptor negative and progesterone receptor negative All or part of first course of treatment performed at the reporting facility Known to be alive within 4 months (120 days) of diagnosis

1.20 Types of Data Sources

Registry data

6.1.2 Current or Planned Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization), Regulatory and Accreditation Programs

6.1.3 Current Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization), Regulatory and Accreditation Programs

Exclusions

Exclude, if any of the following characteristics are identified:

Men

Age < 18 and >= 70

Not the first or only cancer diagnosis

Tumor not originating in the breast

Non-epithelial malignancies, exclude 8200 - adenoid cystic carcinoma and rare tumors (8940 -

Mixed tumor, malignant, NOS; 8950 - Mullerian mixed tumor; 8980 - Carcinosarcoma; 8981 - Carcinosarcoma, embryonal)

Non-invasive tumors

ER positive

PR positive

Evidence of in situ or metastatic disease

None of 1st course therapy performed at reporting facility

No surgical procedure of the primary site

Died within 4 months (120 days) of diagnosis
Participation in a clinical trial which directly impacts the delivery of the standard of care
Not AJCC T1cN0M0 or not AJCC Stage IB-IIIC

Risk Adjustment

No risk adjustment or risk stratification

Target Population

Elderly

Use In Federal Program

Hospital Compare, Prospective Payment System (PPS)-Exempt Cancer Hospital Quality Reporting

Steward Organization

American College of Surgeons

Steward POC email

bpalis@facs.org